A first-of-its-kind blood test to detect amyloid plaques in the brain associated with Alzheimer’s disease recently received clearance from the U.S. Food and Drug Administration. An Indiana University School of Medicine researcher who helped lead the discovery and development of one of the biomarkers the test identifies hopes it will provide greater access and a more accurate diagnosis for patients.